Otters overwhelm shellfish fisheries, First Nations on B.C.’s coast

By Cara McKenna, The Canadian Press

VANCOUVER – How many otters is too many?

In the early 1900’s, these adorable-but-ferocious predators were hunted to near extinction for their luxurious fur.

With continual conservation efforts, the sea otter population is growing, and along with it the marine mammal’s appetite for shellfish.

First Nations and other shellfish harvesters say the sea otter’s rebound is hurting their bottom line.

But the population evidence is anecdotal, so Simon Fraser University assistant Prof. Anne Salomon will be spending the next three years trying to uncover their impact.

Salomon has worked with sea otters for 12 years, and describes them as cute and cuddly from far away, but up close “they’re as big as a German shepherd with very big teeth.”

Salomon has received a $150,000 fellowship — the Pew Fellowship — that will allow her to study how human interference on marine life is changing food chains along the coast of B.C. and Alaska.

She will be working closely with First Nations communities in her research, gathering traditional knowledge and oral histories along with scientific research in an attempt to figure out what is “normal” for the otter population, based on the level before they were hunted for their fur.

“The big question is, really, what is the baseline that we should be recovering these sea otters to,” said Salomon.

She said the sea otter is in direct competition for shellfish with harvesters and conflicts are emerging.

“They’re only going to arise even more as these very cute, but very effective, predators expand along our coastline.”

Sea otters have huge molars and need to eat a lot because of their lack of body insulation and high activity, she explained, so they crunch shellfish quickly and efficiently.

Roberta Stevenson, executive director of the BC Shellfish Grower’s Association, said otters are hard on wild shellfish populations.

Stevenson said she knows divers who have gone for geoducks, only to find empty beds, cratered like a moonscape because the otters got there first.

“The sea otter is a protected species by DFO (Fisheries and Oceans Canada), and it shouldn’t be,” said Stevenson.

“If you ever go out on the West Coast, as far as the eye can see they’re rafting up on the kelp beds. There are tons of them.”

Salomon said kelp beds increase as sea otters do.

This is because otters eat creatures that normally dine on kelp such as sea urchins.

These lush kelp beds are beneficial, she said, because they create a habitat for creatures like rockfish and siphon carbon from the atmosphere, controlling carbon emissions.

According to Salomon, it is the contrasts in positive and negative impacts like this that creates stark differences in people’s interests.

“I’ve been told by one of my collaborators — Barb Wilson — who’s a Haida Matriarch, that in the past the Haida used to control the sea otter population by hunting male sea otters,” she said.

“It’s a really contentious and a tricky issue, because a lot of people do not like the idea of killing sea otters. Especially since they were once listed as an endangered species.”

Salomon said there is evidence showing the current population of sea otters may be just a third of what it once was, but no one is currently sure of the “right” number. She is hoping her sea otter research will ultimately spark a debate and affect change.

“Sea otters are one kind of catalyzer — or vehicle, if you will — to spark a debate in British Columbia that’s happening right now in our coastal marine planning,” she said.

“This brings into focus some of the main issues that these processes are going to have to deal with. … And those are issues of First Nations entitlement to resources and desired objectives of what we want from our coastal ecosystems.”

Keep it Factual
Add CityNews Toronto as a trusted source on Google to see more local stories from us.

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

4h ago

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

4h ago

Most Watched Today